Diabetic foot infection: Difference between revisions
From IDWiki
No edit summary |
m (Text replacement - " species]]" to "]]") |
||
| (3 intermediate revisions by the same user not shown) | |||
| Line 6: | Line 6: | ||
**[[Staphylococcus aureus]], which is by far the most common cause of monomicrobial infections |
**[[Staphylococcus aureus]], which is by far the most common cause of monomicrobial infections |
||
**[[Coagulase-negative staphylococci]] |
**[[Coagulase-negative staphylococci]] |
||
| − | **[[Streptococcus |
+ | **[[Streptococcus]] |
| − | **[[ |
+ | **[[Enterococcus]] |
**[[Enterobacteriaceae]] |
**[[Enterobacteriaceae]] |
||
**[[Pseudomonas aeruginosa]] |
**[[Pseudomonas aeruginosa]] |
||
**[[Anaerobes]], including [[Bacteroides fragilis]] |
**[[Anaerobes]], including [[Bacteroides fragilis]] |
||
*Anaerobes are more likely to be involved in deeper, more chronic ulcers |
*Anaerobes are more likely to be involved in deeper, more chronic ulcers |
||
| + | |||
| + | ==Diagnosis== |
||
| + | |||
| + | *Osteomyelitis should be considered in all cases of diabetic foot infection |
||
| + | **[[Probe-to-bone test]] should be done routinely |
||
| + | **Plain film X-ray can be helpful, though not sensitive |
||
| + | **MRI is the preferred diagnostic test, followed by bone and white cell scan |
||
| + | **The gold standard is still bone biopsy for histopathology and culture |
||
==Management== |
==Management== |
||
| Line 21: | Line 29: | ||
|- |
|- |
||
| rowspan="7" |Mild |
| rowspan="7" |Mild |
||
| − | | rowspan="5" |methicillin-susceptible [[Staphylococcus aureus]], [[Streptococcus |
+ | | rowspan="5" |methicillin-susceptible [[Staphylococcus aureus]], [[Streptococcus]] |
|[[dicloxacillin]] |
|[[dicloxacillin]] |
||
|qid dosing and very narrow-spectrum |
|qid dosing and very narrow-spectrum |
||
| Line 45: | Line 53: | ||
|- |
|- |
||
| rowspan="13" |moderate or severe |
| rowspan="13" |moderate or severe |
||
| − | | rowspan="9" |[[MSSA]], [[Streptococcus |
+ | | rowspan="9" |[[MSSA]], [[Streptococcus]], [[Enterobacteriaceae]], [[anaerobes]] |
|[[levofloxacin]] |
|[[levofloxacin]] |
||
|suboptimal against MSSA |
|suboptimal against MSSA |
||
| Line 86: | Line 94: | ||
|[[piperacillin-tazobactam]] |
|[[piperacillin-tazobactam]] |
||
| |
| |
||
| + | |} |
||
| + | |||
| + | ===Duration=== |
||
| + | {| class="wikitable" |
||
| + | !Site of Infection |
||
| + | !Severity |
||
| + | !Duration |
||
| + | |- |
||
| + | | rowspan="3" |soft tissue only |
||
| + | |mild |
||
| + | |1 to 2 weeks; up to 4 weeks if slow-to-resolve |
||
| + | |- |
||
| + | |moderate |
||
| + | |1 to 3 weeks |
||
| + | |- |
||
| + | |severe |
||
| + | |2 to 4 weeks |
||
| + | |- |
||
| + | | rowspan="4" |bone and joint infection |
||
| + | |postamputation, with no residual infection |
||
| + | |2 to 5 days |
||
| + | |- |
||
| + | |postamputation, with residual soft tissue infection |
||
| + | |1 to 3 weeks |
||
| + | |- |
||
| + | |postamputation, with residual bone infection |
||
| + | |4 to 6 weeks |
||
| + | |- |
||
| + | |no surgery |
||
| + | |≥3 months |
||
|} |
|} |
||
Latest revision as of 00:02, 28 January 2022
Background
Microbiology
- Typically polymicrobial, including:
- Staphylococcus aureus, which is by far the most common cause of monomicrobial infections
- Coagulase-negative staphylococci
- Streptococcus
- Enterococcus
- Enterobacteriaceae
- Pseudomonas aeruginosa
- Anaerobes, including Bacteroides fragilis
- Anaerobes are more likely to be involved in deeper, more chronic ulcers
Diagnosis
- Osteomyelitis should be considered in all cases of diabetic foot infection
- Probe-to-bone test should be done routinely
- Plain film X-ray can be helpful, though not sensitive
- MRI is the preferred diagnostic test, followed by bone and white cell scan
- The gold standard is still bone biopsy for histopathology and culture
Management
| Severity | Common Pathogens | Antibiotics | Notes |
|---|---|---|---|
| Mild | methicillin-susceptible Staphylococcus aureus, Streptococcus | dicloxacillin | qid dosing and very narrow-spectrum |
| clindamycin | active against MRSA but higher risk of CDAD | ||
| cephalexin | qid dosing | ||
| levofloxacin | not as effective against Staphylococcus aureus | ||
| amoxicillin-clavulanic acid | broad-spectrum, includes anaerobic coverage | ||
| methicillin-resistant Staphylococcus aureus | doxycycline | uncertain activity against streptococci | |
| TMP-SMX | uncertain activity against streptococci | ||
| moderate or severe | MSSA, Streptococcus, Enterobacteriaceae, anaerobes | levofloxacin | suboptimal against MSSA |
| cefoxitin | |||
| ceftriaxone | |||
| ampicillin-sulbactam | |||
| moxifloxacin | |||
| ertapenem | |||
| tigecycline | |||
| fluoroquinolone with clindamycin | |||
| imipenem-cilastatin | |||
| MRSA | linezolid | ||
| daptomycin | |||
| vancomycin | |||
| Pseudomonas aeruginosa | piperacillin-tazobactam |
Duration
| Site of Infection | Severity | Duration |
|---|---|---|
| soft tissue only | mild | 1 to 2 weeks; up to 4 weeks if slow-to-resolve |
| moderate | 1 to 3 weeks | |
| severe | 2 to 4 weeks | |
| bone and joint infection | postamputation, with no residual infection | 2 to 5 days |
| postamputation, with residual soft tissue infection | 1 to 3 weeks | |
| postamputation, with residual bone infection | 4 to 6 weeks | |
| no surgery | ≥3 months |
- Osteomyelitis
- Traditionally, 6 weeks of parenteral therapy
- May be able to shorten to 3 weeks if adequately debrided, based on more recent evidence1
Further Reading
- The Neuropathic Diabetic Foot Ulcer Microbiome IsAssociated With Clinical Factors. Diabetes. 2013;62:923-930.
References
- ^ Karim Gariani, Truong-Thanh Pham, Benjamin Kressmann, François R Jornayvaz, Giacomo Gastaldi, Dimitrios Stafylakis, Jacques Philippe, Benjamin A Lipsky, İlker Uçkay. Three versus six weeks of antibiotic therapy for diabetic foot osteomyelitis: A prospective, randomized, non-inferiority pilot trial. Clinical Infectious Diseases. 2020. doi:10.1093/cid/ciaa1758.
